Andrew Huberman· PhD
So it's, you know, in open label studies, it's closer to like half to 2/3 of people end up getting better depending upon their level of treatment resistance.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
So it's, you know, in open label studies, it's closer to like half to 2/3 of people end up getting better depending upon their level of treatment resistance.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
In the blinded trials it was more like 1/3 or so of people, you know, experienced relief.